Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $112.6 million.

  • Axsome Therapeutics' Non-cash Items rose 215088.31% to $112.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.6 million, marking a year-over-year increase of 215088.31%. This contributed to the annual value of $146.6 million for FY2024, which is 950.62% down from last year.
  • As of Q3 2025, Axsome Therapeutics' Non-cash Items stood at $112.6 million, which was up 215088.31% from $133.8 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Non-cash Items ranged from a high of $318.3 million in Q1 2024 and a low of $3.2 million during Q2 2022
  • Its 4-year average for Non-cash Items is $126.7 million, with a median of $133.8 million in 2025.
  • Its Non-cash Items has fluctuated over the past 5 years, first crashed by 9641.76% in 2023, then soared by 440522.94% in 2024.
  • Axsome Therapeutics' Non-cash Items (Quarter) stood at $300.7 million in 2022, then tumbled by 46.12% to $162.0 million in 2023, then dropped by 9.51% to $146.6 million in 2024, then dropped by 23.19% to $112.6 million in 2025.
  • Its Non-cash Items was $112.6 million in Q3 2025, compared to $133.8 million in Q2 2025 and $148.8 million in Q1 2025.